What's new? Log in Free sign up

Longboard Pharmaceuticals (LBPH)

Company Profile

Company profile

Ticker

LBPH

Exchange

Website

www.longboardpharma.com

CEO

Mr. Kevin R. Lind

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Alabama Power • Mississippi Power • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris ...

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Material Contracts & Credit Agreements

Subsidiaries Lists

LBPH stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Securities registration termination

Automatic shelf registration (post-effective amendment)

Withdrawal of registration withdrawal request

Notice of effectiveness

Notice of effectiveness

Notice of effectiveness

Registration withdrawal request

Registration of securities for employees (post-effective amendment)

Registration of securities for employees (post-effective amendment)

Registration of securities for employees (post-effective amendment)

Transcripts

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

Goff Corinne Le

PHILLIP M SCHNEIDER

Vincent Aurentz

Kevin Robert Lind

Cormorant Asset Management, LP

Financial summary

Financial statements Chart LBPH financial data

Quarter (USD)	Sep 24	Jun 24	Mar 24	Dec 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	27.85 mm	27.85 mm	27.85 mm	27.85 mm	27.85 mm	27.85 mm
Cash burn (monthly)	(no burn)	(no burn)	9.37 mm	7.29 mm	6.87 mm	5.49 mm
Cash used (since last report)	n/a	n/a	37.71 mm	29.31 mm	27.61 mm	22.10 mm
Cash remaining	n/a	n/a	-9.85 mm	-1.46 mm	240.15 k	5.75 mm
Runway (months of cash)	n/a	n/a	-1.1	-0.2	0.0	1.0

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

LBPH institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	128	103	+24.3%
Opened positions	35	20	+75.0%
Closed positions	10	21	-52.4%
Increased positions	54	48	+12.5%
Reduced positions	27	27	–

13F shares	Current	Prev Q	Change
Total value	1.21 tn	965.04 bn	+24.9%
Total shares	47.86 mm	44.94 mm	+6.5%
Total puts	13.90 k	31.10 k	-55.3%
Total calls	28.90 k	8.50 k	+240.0%
Total put/call ratio	0.5	3.7	-86.9%

Largest owners	Shares	Value	Change
FMR	4.35 mm	$144.99 bn	-1.5%
ARNA Arena Pharmaceuticals	3.98 mm	$19.42 mm	0.0%
Farallon Capital Management	3.15 mm	$105.02 bn	+7.2%
Farallon Capital Partners	3.09 mm	$184.72 mm	+164.9%
T. Rowe Price	2.91 mm	$96.97 mm	+16.0%
BlackRock	2.84 mm	$94.59 bn	NEW
Cormorant Asset Management	2.79 mm	$93.01 bn	0.0%
Vanguard	2.03 mm	$67.76 bn	+5.6%
Viking Global Investors	1.97 mm	$65.63 bn	+18.7%
Wellington Management	1.59 mm	$53.00 bn	-10.6%

Largest transactions	Shares	Bought/sold	Change
Ra Capital Management	0.00	-3.29 mm	EXIT
BlackRock	2.84 mm	+2.84 mm	NEW
BLK BlackRock	0.00	-2.37 mm	EXIT
Farallon Capital Partners	3.09 mm	+1.93 mm	+164.9%
Point72 Asset Management	0.00	-1.03 mm	EXIT
Woodline Partners	1.00 mm	+940.27 k	+1459.2%
Siren, L.L.C.	903.23 k	+903.23 k	NEW
GS The Goldman Sachs Group, Inc.	1.03 mm	+701.76 k	+216.0%
JPM JPMorgan Chase & Co.	98.00 k	-508.60 k	-83.8%
Emerald Advisers	683.64 k	+455.12 k	+199.2%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

LBPH insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
2 Dec 24	Randall Kaye	Common Stock		Dispose U	No	No	60	30,554	1.83 mm	0
2 Dec 24	Randall Kaye	RSU Common Stock	Sale back to company	Dispose D	No	No	0	9,500	0.00	0
2 Dec 24	Randall Kaye	RSU Common Stock	Sale back to company	Dispose D	No	No	0	17,920	0.00	0
2 Dec 24	Randall Kaye	Employee Stock Option Common Stock	Sale back to company	Dispose D	No	No	19.32	107,560	2.08 mm	0
2 Dec 24	Randall Kaye	Employee Stock Option Common Stock	Sale back to company	Dispose D	No	No	4.35	96,300	418.90 k	0
2 Dec 24	Randall Kaye	Employee Stock Option Common Stock	Sale back to company	Dispose D	No	No	6	175,946	1.06 mm	0
2 Dec 24	Roberts Brandi	RSU Common Stock	Sale back to company	Dispose D	No	No	0	7,900	0.00	0
2 Dec 24	Roberts Brandi	RSU Common Stock	Sale back to company	Dispose D	No	No	0	15,090	0.00	0
2 Dec 24	Roberts Brandi	Employee Stock Option Common Stock	Sale back to company	Dispose D	No	No	19.32	90,580	1.75 mm	0
2 Dec 24	Roberts Brandi	Employee Stock Option Common Stock	Sale back to company	Dispose D	No	No	4.35	119,700	520.69 k	0

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Deal Dispatch: Ubisoft In Buyout Talks, Dental Supplier Explores Sale, Beloved Drive-Through Goes Bankrupt

Dental supply maker Patterson Companies Inc announced Thursday that it is exploring strategic options, including a sale or merger, to boost shareholder value.

Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies; DEEp OCEAN Is The First Pivotal Clinical Trial Designed To Study DEEs Broadly

DEEp OCEAN is the first pivotal clinical trial designed to study DEEs broadlyInitial sites activated with additional sites expected to be activated in the coming weeksLongboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a

Longboard Pharmaceuticals Q3 2024 GAAP EPS $(0.63) Misses $(0.57) Estimate

Longboard Pharmaceuticals (NASDAQ:LBPH) reported quarterly losses of $(0.63) per share which missed the analyst consensus estimate of $(0.57) by 10.53 percent.

Press releases

From Benzinga Pro

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates B, LBPH, ZUO on Behalf of Shareholders

NEW YORK, Nov. 12, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties

Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs)

DEEp OCEAN is the first pivotal clinical trial designed to study DEEs broadly Initial sites activated with additional sites expected to be activated in the coming weeks Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Positive opinion of Paediatric Investigation Plan for bexicaserin issued by European Medicines Agency (EMA) Paediatric Committee (PDCO) for children down to the age of 2 years Recently initiated Phase 3 global

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.